SCHEMBL230453

SCHEMBL230453

COC(=O)c1csc(N)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.65
ALDH1A1 P00352 6/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
NPC1 O15118 2/20 0.65
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 4/20 0.50
LMNA P02545 1/20 0.50
MAOA P21397 1/20 0.49
ACHE P22303 1/20 0.49
NOS1 P29475 1/20 0.42
HSD17B10 Q99714 3/20 0.42
GABRA5 P31644 1/20 0.42
GABRB2 P47870 1/20 0.42
KDM4E B2RXH2 3/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5929889 0.98 MAPT (0.63) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL22887541 0.82 ALDH1A1 (0.62) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL1808115 0.82 L3MBTL1 (0.54) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL12241845 0.81 ALDH1A1 (0.45) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL28518579 0.81 MAPT (0.53) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL7105641 0.81 MAPT (0.53) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL7105645 0.81 MAPT (0.53) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL220846 0.80 RAB9A (0.97) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL12862528 0.80 ALDH1A1 (0.59) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL1368990 0.80 ALDH1A1 (0.59) MAPTALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777051-B Synthesis method of 2-bromo-5-chlorothiazole-4-carboxylate 山西永津集团有限公司 2024-07-02 CN claimed
CN-117777051-A Synthesis method of 2-bromo-5-chlorothiazole-4-carboxylate 山西永津集团有限公司 2024-03-29 CN claimed
CN-107228909-B Method for measuring acotiamide hydrochloride raw material medicine and related substances in preparation thereof by using HPLC 中美华世通生物医药科技(武汉)股份有限公司 2021-05-28 CN claimed
CN-109438437-B Thiazole ring-containing anticancer compound 深圳市第二人民医院 2020-07-17 CN claimed
CN-109438437-A Anticancer compound of the one kind containing thiazole ring 深圳市第二人民医院 2019-03-08 CN claimed
CN-108484443-A A kind of cyanogen flutolanil compound and its preparation method and application with antibacterial activity 华南农业大学 2018-09-04 CN claimed
US-7687490-B2 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2010-03-30 US claimed
CN-101193891-A 2-thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA (JP) 2008-06-04 CN claimed
EP-1870412-A1 2-THIOETHENYL CARBAPENEM DERIVATIVE MEIJI SEIKA KAISHA LTD. (JP) 2007-12-26 EP claimed
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MEIJI SEIKA KAISHA, LTD. (JP) 2007-01-04 US claimed
EP-4590666-A1 THIAZOLE DERIVATIVES AS TAU AGGREGATION INHIBITORS WisTa Laboratories Ltd. (SG) 2025-07-30 EP disclosed
CN-119894874-A Thiazole derivatives as TAU aggregation inhibitors 维斯塔实验室有限公司 2025-04-25 CN disclosed
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 EP disclosed
CN-114630822-B Biaryl dihydroorotate acid dehydrogenase inhibitors 詹森生物科技公司 2024-10-01 CN disclosed
CN-117777051-B Synthesis method of 2-bromo-5-chlorothiazole-4-carboxylate 山西永津集团有限公司 2024-07-02 CN disclosed
WO-2000058293-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 WO disclosed
US-6121301-A ADMINISTERING TO PREVENT OR TREAT GASTROINTESTINAL DYSMOTILITY; COMPOUNDS SUCH AS 2-((N-(3-CYANOBENZOYL)AMINO)-4-((3-DIISOPROPYLAMINOPROPYL)AMINOCARBONYL)-1,3-THIAZOLE ZERIA PHARMACEUTICAL CO., LTD. (JP) 2000-09-19 US disclosed
CN-1261357-A Process for preparing 2-hydroxybenzamide derivatives ZERIA PHARM CO LTD (JP) 2000-07-26 CN disclosed
EP-0994108-A1 PROCESS FOR PRODUCING 2-HYDROXYBENZAMIDE DERIVATIVES ZERIA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
EP-0934938-A1 SUBSTITUTED BENZOYLAMINOTHIAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME ZERIA PHARMACEUTICAL CO., LTD. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004700-A1 2-Thioethenyl substituted carbapenem derivatives MTAP, BLVRB, BPGM MAPT 3579/4885ALDH1A1 1182/4885MEN1 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.